Alopecia areata
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Alopecia areata inoonekwa kuseri kwemusoro. Muzviitiko zvakajairwa, inooneka kamwe kamwe ine nzvimbo yakatsetseka uye saizi ye2-3 cm.
References
Alopecia areata ndiyo mamiriro ekuti immune system yako inorwisa mafollicle ebvudzi rako, zvichitungamira mukurasikirwa kwebvudzi kwenguva pfupi pasina vanga. Inogona kuratidza sezvigamba zvekurasika bvudzi kana kukanganisa ganda rako rose kana muviri, zvichikanganisa 2% yevanhu pane imwe nguva muhupenyu hwavo. Mhosva huru inoratidzika kuva kuparara kwekuchengetedzwa kwechisikigo kwakapoteredza bvudzi rebvudzi.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata imamiriro ekuti immune system inorwisa mafollicles ebvudzi, zvichikonzera kurasikirwa kwebvudzi pamusoro pemusoro uye dzimwe nhengo dzine mvere dzemuviri. Inobata zvakapoteredza 2% yevanhu pasi rose. Kunyange zvichigona kuitika chero zera, zvinowanzoitika muvana pane vakuru (1. 92% vs. 1. 47%) . Vakadzi, kunyanya avo vanopfuura makumi mashanu, vanowanzosangana nazvo kupfuura varume. Kubaya majekiseni ecorticosteroids munzvimbo dzakakanganisika kwaratidza zvibereko zviri nani pane kuashandisa pamusoro.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata inotendwa sechirwere che autoimmune chine chekuita ne immune system yebvudzi follicles. Iyo yepasi maitiro inosanganisira kutadza nemuviri kuziva masero awo, nekuzotevera immune-mediated kuparadzwa kwebvudzi follicle.
○ Kurapa ― OTC Zvinodhaka
Vamwe vanhu vane nyoro alopecia areata vanopora mukati megore vasina kurapwa. Nekudaro, vanhu vazhinji vanosangana nekudzokorora panzvimbo dzakangoitika paganda remusoro.
#Hydrocortisone cream
○ Kurapwa
Intralesional steroid majekiseni ndiyo inonyanya kurapa. Immunotherapy inogona kuyedzwa kana nzvimbo huru dzemusoro dzikakanganiswa.
#Triamcinolone intralesional injection
#DPCP immunotherapy